Pembrolizumab in gevorderd plaveiselcelcarcinoom van het hoofd en de nek

Redactie Medicalfacts/ Janine Budding 04 juni 2015 - 17:55
Array

Chicago ASCO Annual Meeting 2015: Press Briefing Immunotherapie: vrijdag, 29 mei Tanguy Y. Seiwert, Robert I. Haddad, Shilpa Gupta, et. al. Antitumor activiteit en veiligheid van pembrolizumab bij patiënten (pts) met gevorderd plaveiselcelcarcinoom van het hoofd en de nek (SCCHN): Voorlopige resultaten van KEYNOTE-012 uitbreiding cohort.

Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.

Background: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that blocks interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby promoting activity of tumor-specific effector T cells. KEYNOTE 012 (NCT01848834) had previously demonstrated clinical activity of pembrolizumab 10 mg/kg every 2 weeks in patients (pts) with recurrent/metastatic SCCHN enriched for PD-L1–positive tumors with a response rate of 20%. We now report on the larger SCCHN expansion cohort of KEYNOTE 012, irrespective of biomarker status using a 3-weekly fixed dose.

Methods: Pts with advanced SCCHN irrespective of PD-L1 expression or HPV status received a fixed dose of 200 mg pembrolizumab, intravenously, every 3 weeks. Pts were evaluated every 8 weeks with radiographic imaging. The primary end point was overall response rate (ORR) per investigator assessment (RECIST 1.1). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Adverse events (AEs) were assessed according to CTCAE v4. PD-L1 was assessed retrospectively by immunohistochemistry.

Results: 132 pts with recurrent/metastatic SCCHN were enrolled. Mean (SD) age was 58.9 (9.7) years; 83.3% were male; 56.8% had ? 2 lines of therapy for recurrent disease. 73/132 pts (55.3%) remain on treatment. Out of 132 treated pts, 99 pts were available for this preliminary efficacy analysis with a post-baseline scan or discontinued therapy prior to the scan due to clinical progression or AE. ORR (confirmed and unconfirmed) per RECIST 1.1 was 18.2% (95% CI, 11.1-27.2) with 18 partial responses and 31.3% with stable disease. Biomarker analysis is ongoing and results will be presented. Drug-related AEs of any grade occurred in 47% of all enrolled pts, and drug-related grade ? 3 AEs occurred in 7.6%. The most common drug-related AEs ( ? 5%) of any grade were fatigue (12.1%), decreased appetite (6.8%), pyrexia (6.1%), and rash (5.3%).

Conclusions: Pembrolizumab given at a fixed dose of 200 mg every 3 weeks was well tolerated and demonstrated a clinically meaningful ORR of 18.2% in pts with recurrent/metastatic SCCHN. Clinical trial information: NCT01848834

Subcategory: 
Head and Neck Cancer
Category: 
Head and Neck Cancer
Meeting: 
2015 ASCO Annual Meeting
Session Type and Session Title:
Oral Abstract Session, Head and Neck Cancer

Abstract Number: LBA6008

Citation: 
J Clin Oncol 33, 2015 (suppl; abstr LBA6008)
Author(s): 
Tanguy Y. Seiwert, Robert I. Haddad, Shilpa Gupta, Ranee Mehra, Makoto Tahara, Raanan Berger, Se-Hoon Lee, Barbara Burtness, Dung T. Le, Karl Heath, Amy Blum, Marisa Dolled-Filhart, Kenneth Emancipator, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q. Chow; The University of Chicago, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Fox Chase Cancer Center, Philadelphia, PA; National Cancer Center Hospital East, Kashiwa, Japan; Sheba Medical Center, Tel HaShomer, Israel; Seoul National University Hospital, Seoul, South Korea; Yale Cancer Center, Yale School of Medicine, New Haven, CT; Sidney Kimmel Comprehensive Cancer Center at JHU, Baltimore, MD; Merck & Co., Inc., Kenilworth, NJ; Department of Medicine, Division of Oncology, University of Washington, Seattle, WA
Abstract Disclosures

 

Redactie Medicalfacts/ Janine Budding

Ik heb mij gespecialiseerd in interactief nieuws voor zorgverleners, zodat zorgverleners elke dag weer op de hoogte zijn van het nieuws wat voor hen relevant kan zijn. Zowel lekennieuws als nieuws specifiek voor zorgverleners en voorschrijvers. Social Media, Womens Health, Patient advocacy, patient empowerment, personalized medicine & Zorg 2.0 en het sociaal domein zijn voor mij speerpunten om extra aandacht aan te besteden.

Ik studeerde fysiotherapie en Health Care bedrijfskunde. Daarnaast ben ik geregistreerd Onafhankelijk cliëntondersteuner en mantelzorgmakelaar. Ik heb veel ervaring in diverse functies in de zorg, het sociaal domein en medische-, farmaceutische industrie, nationaal en internationaal. En heb brede medische kennis van de meeste specialismen in de zorg. En van de zorgwetten waaruit de zorg wordt geregeld en gefinancierd. Ik ga jaarlijks naar de meeste toonaangevende medisch congressen in Europa en Amerika om mijn kennis up-to-date te houden en bij te blijven op de laatste ontwikkelingen en innovaties. Momenteel ben doe ik een Master toegepaste psychologie.

De berichten van mij op deze weblog vormen geen afspiegeling van strategie, beleid of richting van een werkgever noch zijn het werkzaamheden van of voor een opdrachtgever of werkgever.

Recente artikelen